Suven Pharmaceuticals has received a long-term credit rating of CRISIL A+/Watch Positive and a short-term rating of CRISIL A1+, reaffirmed by CRISIL Ratings, highlighting the anticipated growth from its proposed amalgamation with Cohance Lifesciences Ltd, which is pending necessary approvals. The groups market position remains strong with a reported revenue of Rs. 1051 crores for fiscal 2024 and Rs. 488 crores in the first half of the current fiscal year.